RAC 2.42% $1.61 race oncology ltd

Is Zantrene the only anti cancer cardio protective cancer...

  1. 2,456 Posts.
    lightbulb Created with Sketch. 2590
    Is Zantrene the only anti cancer cardio protective cancer opportunity?

    In short NO.

    Dexrazoxane and Resveratrol are probably a few examples that I have come across. Although they are few and far between.

    The main issue is safety and potetency of anti cancer in solid tumours as single angle or in combo.

    Zantrene having 60+ trials and 1500 patients dosed is a relatively sound safety profile. Current trials will obviously be needed to test current drug combos.

    Therefore efficacy of treatment and anti cancer properties are shaping up nicely.

    So if cardio protection translates from mouse models to in patient results this seems much more promising. Notably the mouse model used and generally well translated to humans for such cardio based tests.

    Just looking for potential points of failure. If P2 data stacks up and commercially viable then Cardio protect anti cancer can be the new SoC.

    To summarise, cancer treatments damage the heart. Survive from cancer treatments and die from heart disease, not a great outcome.

    Zantrene could be the solution, P2 trials not far away!

    DYOR
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
(20min delay)
Last
$1.61
Change
-0.040(2.42%)
Mkt cap ! $267.8M
Open High Low Value Volume
$1.71 $1.71 $1.54 $370.9K 232.5K

Buyers (Bids)

No. Vol. Price($)
1 392 $1.58
 

Sellers (Offers)

Price($) Vol. No.
$1.61 13999 1
View Market Depth
Last trade - 16.10pm 15/05/2024 (20 minute delay) ?
Last
$1.58
  Change
-0.040 ( 6.08 %)
Open High Low Volume
$1.62 $1.65 $1.54 41933
Last updated 15.58pm 15/05/2024 ?
RAC (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.